DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 3,245 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $61.23, for a total value of $198,691.35. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Andrew K. Balo also recently made the following trade(s):
- On Wednesday, November 29th, Andrew K. Balo sold 6,490 shares of DexCom stock. The stock was sold at an average price of $60.00, for a total value of $389,400.00.
DexCom, Inc. (NASDAQ DXCM) traded down $1.19 on Friday, reaching $57.04. The company had a trading volume of 1,365,832 shares, compared to its average volume of 1,655,871. DexCom, Inc. has a 12-month low of $42.62 and a 12-month high of $88.80. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.
Several hedge funds have recently modified their holdings of the company. AXA increased its position in shares of DexCom by 10.5% during the 3rd quarter. AXA now owns 1,318,931 shares of the medical device company’s stock valued at $64,529,000 after purchasing an additional 124,920 shares during the period. DF Dent & Co. Inc. increased its position in shares of DexCom by 438.2% during the 3rd quarter. DF Dent & Co. Inc. now owns 75,856 shares of the medical device company’s stock valued at $3,711,000 after purchasing an additional 61,762 shares during the period. Neuberger Berman Group LLC increased its position in shares of DexCom by 54.7% during the 3rd quarter. Neuberger Berman Group LLC now owns 385,421 shares of the medical device company’s stock valued at $18,857,000 after purchasing an additional 136,205 shares during the period. California Public Employees Retirement System increased its position in shares of DexCom by 2.0% during the 3rd quarter. California Public Employees Retirement System now owns 129,400 shares of the medical device company’s stock valued at $6,331,000 after purchasing an additional 2,500 shares during the period. Finally, Sessa Capital IM L.P. acquired a new position in shares of DexCom during the 3rd quarter valued at $14,678,000.
A number of brokerages have recently weighed in on DXCM. BidaskClub upgraded DexCom from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. BMO Capital Markets increased their price target on DexCom to $74.00 and gave the stock an “outperform” rating in a research report on Tuesday. Piper Jaffray Companies reiterated a “buy” rating and set a $87.00 price target on shares of DexCom in a research report on Thursday, September 28th. Northland Securities started coverage on DexCom in a research report on Tuesday, September 26th. They issued an “outperform” rating and a $85.00 target price on the stock. Finally, Leerink Swann restated a “buy” rating and issued a $57.00 target price (down from $85.00) on shares of DexCom in a research report on Friday, September 29th. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. DexCom presently has an average rating of “Buy” and an average target price of $71.36.
TRADEMARK VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/16/dexcom-inc-dxcm-evp-andrew-k-balo-sells-3245-shares-of-stock.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.